TG Therapeutics, Inc. (TGTX) financial statements (2021 and earlier)

Company profile

Business Address 2 GANSEVOORT STREET, 9TH FLOOR
NEW YORK, NY 10014
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:605254276781407285
Cash and cash equivalents553254261521134557
Short-term investments52 1526282828
Other undisclosed cash, cash equivalents, and short-term investments(0)00(0)(0)  
Other current assets1122111
Other undisclosed current assets5548878
Total current assets:612260281881498094
Noncurrent Assets
Operating lease, right-of-use asset9999988
Property, plant and equipment0000000
Intangible assets, net (including goodwill)1111111
Goodwill1111111
Regulated entity, other noncurrent assets11222(2)(2)
Restricted cash and investments1111 11
Other undisclosed noncurrent assets1110145
Total noncurrent assets:14141414141312
TOTAL ASSETS:62627429510216393107
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:37353031303231
Other undisclosed accounts payable and accrued liabilities37353031303231
Debt241692211
Deferred compensation liability8531432
Other liabilities18222629494421
Total current liabilities:88786863848056
Noncurrent Liabilities
Long-term debt and lease obligation18253239393837
Long-term debt, excluding current maturities8152229292929
Operating lease, liability101010101098
Liabilities, other than long-term debt1111111
Deferred revenue1111111
Total noncurrent liabilities:19263340403937
Total liabilities:10610310010312411993
Stockholders' equity
Stockholders' equity attributable to parent519171194(1)39(26)1,213
Common stock0000000
Treasury stock, value(0)(0)(0)(0)(0)(0)(0)
Additional paid in capital1,5001,0631,000751740636613
Retained earnings (accumulated deficit)(981)(892)(805)(752)(701)(662)600
Other undisclosed stockholders' equity      (1,199)
Total stockholders' equity:519171194(1)39(26)13
TOTAL LIABILITIES AND EQUITY:62627429510216393107

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues0000000
Amortization of lease incentives(0)  (0)(0)  
Other income(0)000000
Other undisclosed gross profit    3  
Gross profit:0000300
Operating expenses(87)(86)(51)(50)(169)(61) 
Other undisclosed operating income    128 36
Operating income (loss):(87)(86)(51)(50)(38)(61)36
Nonoperating income (expense)(1)(1)(2)(1)(6)11
Interest and debt expense(1)(2)(2)(1)(2)(2)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes6   5  
Income (loss) before gain (loss) on sale of properties:(83)(89)(55)(52)(41)(61)36
Other undisclosed net income (loss)(5)2211(1)0
Net income (loss) available to common stockholders, diluted:(88)(87)(53)(51)(40)(62)36

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net income (loss):(88)(87)(53)(51)(40)(62)36
Comprehensive income (loss), net of tax, attributable to parent:(88)(87)(53)(51)(40)(62)36

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: